Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts

Abstract : Preclinical models based on patient-derived xenografts have remarkable specificity in distinguishing transformed human tumor cells from non-transformed murine stromal cells computationally. We obtained 29 pancreatic ductal adenocarcinoma (PDAC) xenografts from either resectable or non-resectable patients (surgery and endoscopic ultrasound-guided fine-needle aspirate, respectively). Extensive multiomic profiling revealed two subtypes with distinct clinical outcomes. These subtypes uncovered specific alterations in DNA methylation and transcription as well as in signaling pathways involved in tumor-stromal cross-talk. The analysis of these pathways indicates therapeutic opportunities for targeting both compartments and their interactions. In particular, we show that inhibiting NPC1L1 with Ezetimibe, a clinically available drug, might be an efficient approach for treating pancreatic cancers. These findings uncover the complex and diverse interplay between PDAC tumors and the stroma and demonstrate the pivotal role of xenografts for drug discovery and relevance to PDAC.
Complete list of metadatas

Cited literature [29 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01985259
Contributor : Claire Lissalde <>
Submitted on : Thursday, January 17, 2019 - 5:40:05 PM
Last modification on : Friday, November 8, 2019 - 1:46:02 PM

File

mmc6.pdf
Publisher files allowed on an open archive

Identifiers

Collections

Citation

Remy Nicolle, Yuna Blum, Laëtitia Marisa, Céline Loncle, Odile Gayet, et al.. Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts. Cell Reports , Elsevier Inc, 2017, 21 (9), pp.2458-2470. ⟨10.1016/j.celrep.2017.11.003⟩. ⟨inserm-01985259⟩

Share

Metrics

Record views

105

Files downloads

172